This article summarizes a large number of domestic and foreign patents for medical elastic β-type titanium alloy components, focusing on the summary of the research progress of Ti-Nb series, Ti-Mo series, Ti-Zr series and Ti-Ta series alloy components, and points out The future development trend of patent protection of medical elastic β-type titanium alloy components.
Keywords medical; elasticity; β-type; titanium alloy; composition
Medical β-type has become the focus of research and development in various countries due to its advantages of good wear resistance, high corrosion resistance, excellent mechanical properties, and the absence of harmful elements such as V, Al, Ni, Cr and other elements [1]. A patent is an information document that can reflect the latest developments in the level of scientific and technological development. It has a high use value or reference value, making it a leading technical information to promote technological development [2]. This article analyzes and studies the patents of the components of Ti-Nb series, Ti-Mo series, Ti-Zr series and Ti-Ta series alloys mainly developed by medical β-type titanium alloys to understand the broader technical ideas in this field. And the latest technical developments, master the research trends in this field.
- 1 Overview of patent research on medical β-type Ti-Mo alloy components
- 2 Overview of patent research on medical β-type Ti-Nb alloy composition
US4040129 proposes a TiNbZr alloy composed of Ti-30Nb-2Zr, which has a strength of at least 90 kg / mm2 after annealing, quenching and heat treatment. It has good corrosion resistance, biocompatibility, high strength, and is used for shells and dental implants.
JP-A 10-219375A proposes a TiNbTa alloy. The total content of Nb and Ta is 20-60% by weight, and the balance is titanium. The tensile strength is 400-1185MPa, the 0.2% yield strength is 415-1190MPa, the elongation is 3-66, and the elastic modulus is 49-112GPa. It has the characteristics of medium strength, high elongation and low elasticity. At least one of less than 10% Mo, less than 5% zirconium, and less than 5% Sn is further added to the above titanium alloy to improve performance. The preferred components are: Ti-16Nb-7Ta, Ti-18Nb-10Ta-2Mo.
JP 2001-329325A proposes a TiNbSn alloy. The atomic percentage of niobium is 8-20%, and the atomic percentage of tin is 2-6%. And systematically studied the effect of Nb and Sn content changes on performance. - 3 Overview of patent research on medical β-type Ti-Ta alloy components
US4040129 proposes a TiTa alloy with a composition of Ti-5Ta or Ti-30Ta. The tensile strength of Ti-5Ta in the annealed state is 75 kg / mm2; Ti-30Ta is an α + β type alloy, and the tensile strength in the annealed state is 80 kg / mm2. It has good corrosion resistance, biocompatibility, high strength, and is used for shells and dental implants.
JP Sho 62-246372A proposes a TiTa binary solid solution single-phase alloy, whose composition is: 5-35wt% Ta, the balance Ti. The effects of changes in Ta content on alloy strength, corrosion resistance, and biocompatibility were studied. With improved strength and corrosion resistance, it is a safe implant material. - 4 Overview of patent research on medical β-type Ti-Zr alloy components
5 Conclusion
The medical titanium alloy industry, as an emerging industry, is not only a key area for future economic growth, but also an important industry directly related to national health and life safety. Medical β-type titanium alloys are mainly divided into Ti-Nb series, Ti-Mo series, Ti-Zr series and Ti-Ta series alloys, Ti-Nb and Ti-Mo series alloys, which are the focus of current research. The lack of independent intellectual property rights of medical titanium alloy materials will directly restrict the improvement of China’s medical level and reduce the independence of China’s medical technology development. Therefore, it has become an urgent task to increase investment in the research and development of advanced technology for medical titanium alloy materials and strengthen the protection of the independent intellectual property rights of biomedical materials.
